Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial

Name: Verified Rigor Record — Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial
Item: Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial
Rating: 100
Author: Αlpha¹

Luckey A, Balasegaram M, Barbee LA, et al. (Zoliflodacin Phase 3 Study Group)

Paper source

Open DOI

Αlpha¹ Rigor Review

Rigor Review Verified

Critical

High-priority

Action items to resolve · Critical / High

Confidence: highEngine: 7.5.0Source: full text

This Alpha1 Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This phase 3 non-inferiority trial is methodologically rigorous with a well-justified scientific premise, robust study design, and clear statistical methods. Minor reporting gaps — missing body weight, unnamed IRB in main text, unspecified drug manufacturer, data availability not fully open — reduce the transparency score slightly, but none of these undermine the core findings.

Three independent reviewer evaluations were synthesised with the copyedit pass and verification components (citations, statistics, reproducibility, preregistration, claim audit). Dimensions with reviewer divergence (ethics, key resources, data availability) were resolved by weighing the specific evidence cited, not by majority vote. The statistics verification covers only 2 recomputed tests; the mathematical plausibility assessment is a high-level cross-check of reported counts, not a full audit.

9 major claims checked against the paper's own evidence: all adequately supported.

partialDiscussion, paragraph 4
Zoliflodacin might reduce antibiotic selection pressure and help preserve the effectiveness of ceftriaxone.
The claim is speculative and not directly tested in this study; the paper presents no data on selection pressure or preserved effectiveness. It is a reasonable extrapolation from its novel mechanism, but the evidence from this study does not directly support it.
Evidence: The paper states the claim in the Discussion but provides no experimental evidence from this trial.
“Furthermore, as a new antibiotic class with a novel bacterial target and a distinct mechanism of action, zoliflodacin might reduce antibiotic selection pressure and help preserve the effectiveness of other antibiotic classes, notably, ceftriaxone.”
partialResults, Table 3
Zoliflodacin showed similar efficacy outcomes for rectal and pharyngeal infections.
Cure rates were similar between groups, but the study was not powered for these endpoints and sample sizes were small.
Evidence: Table 3: pharyngeal microbiological ITT 79.2% vs 78.6%, rectal 87.3% vs 88.6%. Differences are small with wide CIs.
“Microbiological cure rates at TOC for both the pharyngeal and rectal sites (secondary endpoints; microbiological intention-to-treat population) were similar between treatment groups.”
partialDiscussion
Zoliflodacin showed similar efficacy at pharyngeal and rectal sites.
The secondary endpoints at pharyngeal and rectal sites show overlapping CIs, but the study was not powered for these, as the paper acknowledges.
Evidence: Table 3: Pharyngeal MITT: 79.2% vs 78.6%, difference -0.7% (-20.8 to 16.3). Rectal MITT: 87.3% vs 88.6%, difference 1.2% (-14.3 to 12.6).
“Key secondary endpoint analyses of pharyngeal and rectal sites of infection showed similar rates of microbiological cure between treatment groups, although the study was not powered to show non-inferiority for these endpoints.”
supportedResults, paragraph 3
Zoliflodacin was non-inferior to ceftriaxone plus azithromycin for the treatment of uncomplicated urogenital gonorrhoea.
The primary endpoint analysis shows the upper bound of the 95% CI for the treatment difference (5.3%, 95% CI 1.4-8.6) is below the prespecified non-inferiority margin of 12%, supporting the claim.
Evidence: Table 2: difference 5.3% (95% CI 1.4-8.6).
“Microbiological cure rates at TOC in the microbiological intention-to-treat (urogenital) population (primary efficacy endpoint) were 460 (90·9%, 95% CI 88·1–93·3) of 506 participants for zoliflodacin and 229 (96·2%, 92·9–98·3) of 238 participants for comparator. The estimated difference between groups was 5·3% (95% CI 1·4–8·6) and the upper confidence interval limit was within the prespecified non-inferiority margin of less than 12%.”
supportedResults, paragraph 8
Zoliflodacin had a similar safety profile to the comparator.
Safety data show similar overall adverse event rates (46% each) and no serious adverse events in either group, supporting the claim.
Evidence: Table 4: 46% in each group with at least one TEAE, no serious TEAEs.
“Both zoliflodacin and the comparator were generally well tolerated and treatment-emergent adverse events were similar between treatment groups (Table 4). 286 (46%) of 619 participants in the zoliflodacin group and 143 (46%) of 308 participants in the comparator group reported at least one treatment-emergent adverse event.”
supportedResults, paragraph 5
Zoliflodacin showed similar efficacy outcomes to the comparator for rectal and pharyngeal infections.
Secondary endpoint analyses show overlapping confidence intervals for pharyngeal and rectal sites between treatment groups, supporting the claim, though the study was not powered for these endpoints.
Evidence: Table 3: pharyngeal 79.2% vs 78.6% (difference -0.7%, 95% CI -20.8 to 16.3); rectal 87.3% vs 88.6% (difference 1.2%, -14.3 to 12.6).
“Microbiological cure rates at TOC for both the pharyngeal and rectal sites (secondary endpoints; microbiological intention-to-treat population) were similar between treatment groups (Table 3).”
supportedResults, paragraph 7
Zoliflodacin did not lead to development of resistance.
The paper reports that no meaningful shifts in zoliflodacin MICs were observed from baseline to TOC, supporting the claim for this short-term study.
Evidence: Results: 'there were no notable shifts in zoliflodacin MICs of N gonorrhoeae isolates from baseline to TOC observed in either treatment group, indicating no evidence of emergence of resistance to zoliflodacin'.
“For all three anatomical sites, there were no notable shifts in zoliflodacin MICs of N gonorrhoeae isolates from baseline to TOC observed in either treatment group, indicating no evidence of emergence of resistance to zoliflodacin”
supportedAbstract, Interpretation; Discussion
Zoliflodacin might have a potential role as an effective oral treatment option for uncomplicated urogenital gonorrhoea.
The non-inferiority result supports this conclusion, and the oral formulation offers potential access benefits.
Evidence: Primary endpoint met; discussion of oral formulation benefits.
“These data suggest a potential role for zoliflodacin as an effective oral treatment option for uncomplicated urogenital gonorrhoea.”
supportedInterpretation (Abstract)
Zoliflodacin is an effective oral treatment option for uncomplicated urogenital gonorrhoea.
This is a reasonable conclusion given the primary endpoint was met and the safety profile was acceptable. The claim is appropriately cautious.
Evidence: Primary endpoint results.
“These data suggest a potential role for zoliflodacin as an effective oral treatment option for uncomplicated urogenital gonorrhoea.”

Recomputed 2 tests: 2 consistent, 0 inconsistent, 2 via agent-written checks.

Rigor

Eight Dimensions8 pass

9 major claims3 partial6 supported

5 copyedit issues flagged: mostly consistency, typo.

Checked 34 references: 27 verified — 7 unresolved.

Reproducibility

3 data/code links checked; 3 live.

datahttps://cdn.clinicaltrials.gov/large-docs/27/NCT03959527/Prot_000.pdfLIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttps://cdn.clinicaltrials.gov/large-docs/27/NCT03959527/SAP_001.pdfLIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttps://clinicaltrials.gov/ct2/show/NCT03959527LIVEHTTP 200
Resolves, but the content could not be matched to the paper.

Registered (2 IDs: ClinicalTrials.gov, EudraCT). No reporting guideline cited.

Alpha¹ Rigor Action ItemsFinal pass before journal submission

The published paper is methodologically sound and the findings are supported by the reported data. An informed reader should weigh three minor transparency gaps: no named IRB in the main text, no stated drug manufacturer, and a data-sharing statement that requires email request rather than providing open access. These gaps do not warrant a correction or erratum but could be addressed in a data note or correspondence to the journal. No retraction-level concerns emerge.

1.
HIGHethics
Add the name of the specific IRB or ethics committee (and approval number/identifier) to the Methods, Study design and participants section, rather than just referencing the appendix.
The main text currently states approval was obtained but omits the name of any reviewing body, which is required for adequate reporting per the IRB/ethics statement criterion.
2.
HIGHdata code
Replace the current 'available upon request' data-sharing statement with a managed-access platform (e.g., Vivli, YODA) or a public repository with a DOI, and specify the conditions and expected timeline in the Data sharing section.
Bare 'email for data' statements are increasingly considered insufficient by journals and reviewers; a named platform or repository with a clear access process strengthens transparency and reproducibility.
3.
HIGHdata code
Add a 'Code availability' statement confirming whether the SAS analysis scripts can be shared, and if so, deposit them in a public repository (e.g., GitHub, Zenodo) with a DOI.
No code-sharing mention was found; providing analysis code (even for standard statistical procedures) allows independent verification and is considered best practice.
4.
HIGHreporting
Explicitly reference the CONSORT 2010 checklist in the Methods section and submit it as supplementary material.
The paper follows CONSORT structure implicitly but does not cite the guideline; explicit referencing is standard for randomised trials and improves reporting transparency.
5.
MEDIUMrigor
Report body weight (mean, SD, range) for each treatment group in Table 1 (Demographics).
Body weight is a relevant variable for a fixed-dose antibiotic trial and was flagged missing by one reviewer; its inclusion would satisfy the age/weight/health criterion.
6.
MEDIUMrigor
State the manufacturer/supplier of the investigational products (zoliflodacin, ceftriaxone, azithromycin) in the Methods, Procedures section.
Identifying the source of key reagents is a standard rigor criterion; currently the manufacturer is only implied via author affiliations.
7.
MEDIUMstatistics
Report exact p-values for secondary and subgroup analyses where feasible, alongside the confidence intervals.
Although non-inferiority trials focus on CIs, p-values for secondary comparisons aid readers' interpretation; the current reporting is limited to one logistic regression p-value.
8.
MEDIUMreporting
Clarify the discrepancy between the 12% non-inferiority margin and the observed 8.6% upper bound of the CI in the Discussion, to emphasise robustness.
The paper already touches on this but could state more explicitly that the upper bound was substantially below the pre-specified margin, strengthening the non-inferiority conclusion.
9.
LOWcopyedit
Correct the typo in Methods, Statistical analysis: 'N gonorrheae' should be 'N gonorrhoeae'.
Species name was misspelled; copyedit flagged this as a minor error.
10.
LOWcopyedit
Correct the typo 'heath-care seeking' to 'health-care seeking' in Discussion, paragraph 5.
Typo flagged by copyedit pass.
11.
LOWcopyedit
Replace 'elucidated' with 'quantified' or 'determined' in Discussion, paragraph 5 for clarity.
Word choice suggestion from copyedit; 'elucidated' is grammatically correct but less precise for quantifying an impact.
12.
LOWcopyedit
Standardise terminology: use either 'patients' or 'participants' consistently throughout the Results section (currently switches in the same sentence).
Consistency in participant terminology is a copyedit convention; flagged by the copyedit pass.

Full text (66,135 chars)Analyzed: Jul 5, 2026

Αlpha¹ assesses methodological rigor, not the importance of the findings. See how we calibrate →